investors & media
NASDAQ: (common stock)
Copyright West LLC. Minimum 15 minutes delayed.
Up to 3.8 years of transfusion independence in Phase 1/2 Northstar (HGB-204) study in patients with TDT who do not have a β 0 /β 0 genotype Four of five evaluable patients achieved transfusion independence in ongoing Phase 3 Northstar-2 (HGB-207) study of patients with TDT who do not have a β 0 /βRead more
In patients who were at least six months post-treatment with LentiGlobin for SCD, median level of abnormal sickle hemoglobin (HbS) was reduced to ≤50 percent of total Hb At up to 15 months post-treatment with LentiGlobin, there were no reports of serious vaso-occlusive crisis or acute chestRead more
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 6, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the company will host a live webcast to review new data presented at the European Hematology Association (EHA) Annual Meeting, and to discuss the approval of ZYNTEGLO ® (autologous CD34+ cellsRead more